| KING'S COLLEGE LONDON Patent applications |
| Patent application number | Title | Published |
|---|
| 20120077771 | COMPOSITIONS FOR USE IN CARDIOPLEGIA COMPRISING ESMOLOL AND ADENOSINE - The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM. The invention also relates to methods of making and using such compositions. | 03-29-2012 |
| 20120071337 | METHODS - The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated. | 03-22-2012 |
| 20120058917 | Nucleic Acids and Libraries - The invention relates to a nucleic acid comprising the following contiguous elements arranged in the 5 prime to 3 prime direction; a promoter; a selectable marker; a cloning site for receipt of a nucleic acid segment, said segment comprising a candidate miRNA target sequence; and a poly adenylation signal, said elements arranged such that a transcript directed by said promoter comprises said selectable marker, said candidate miRNA target sequence, and said poly adenylation signal in that order. Suitably the miRNA test sequence is or is derived from a 3′UTR. The invention also relates to methods for making and screening libraries. | 03-08-2012 |
| 20110212076 | Viral Therapeutic - The invention provides a method of inhibiting viral infection of a mammalian cell, said method comprising reducing or inhibiting ps20 polypeptide expressed by said cell. Suitably ps20 is inhibited by contacting said cell with an antibody capable of binding to ps20 polypeptide. Suitably said antibody is ps20 neutralising antibody. The invention also provides antibody capable of binding ps20 polypeptide, siRNA targeted to a transcript encoding ps20 polypeptide, or antisense ps20 polynucleotide for use as a medicament for viral infection. The invention also provides a method of identifying an agent for inhibiting a viral infection, comprising determining level of ps20 expression in first and second samples, the first contacted with test agent; and comparing the level of ps20 expression in said first and second samples; wherein lower level of ps20 expression in said first sample relative to said second sample identifies test agent as an agent for inhibiting a viral infection. | 09-01-2011 |
| 20110210728 | ENHANCING SIGNALS - A method of testing a sample comprising the steps of: applying an excitation to the sample; detecting a response signal from the sample; processing a first part and a second part of the response signal; and determining from the second part of the response signal information with which to enhance the first part of the response signal. | 09-01-2011 |
| 20110117523 | ABRASIVE AGENTS - The present invention relates to the use of a polyalkenoate acid, such as polyacrylic acid or polymaleic acid, in the manufacture of an air abrasive agent for use in conditioning dental tissue, methods of using such air abrasive agents, dental compositions comprising a polyalkenoate acid, air abrasive agents comprising a polyalkenoate acid and at least one of a bioactive glass, a glycine salt, baking soda and alumina, methods of treatment and/or prophylaxis using an air abrasive agent comprising a polyalkenoate acid. | 05-19-2011 |
| 20110025327 | METHOD FOR RADIOFREQUENCY MAPPING IN MAGNETIC RESONANCE IMAGING - A method of mapping a radio frequency magnetic field transmitted to a magnetic resonance imaging specimen. The method comprises the steps of: applying a first radio frequency pulse having a first excitation angle to the specimen and at a first time period after applying the first pulse applying one or more second radio frequency pulses each having a second excitation angle to the specimen, with a second time period between second pulses, to obtain a first data set defining a first sample of an image space; applying one or more third radio frequency pulses each having a third excitation angle to the specimen, with a third time period between third pulses, to obtain a second data set defining a second sample of the image space; applying one or more fourth radio frequency pulses each having a fourth excitation angle to the specimen, with a fourth time period between fourth pulses, to obtain a third data set defining a third sample of the image space; wherein the fourth excitation angle is different to the third excitation angle and/or the fourth time period is different to the third time period; calculating a magnetic field map data from at the three data sets; and outputting the magnetic field map data. | 02-03-2011 |
| 20110019608 | METHOD AND SYSTEM FOR FREQUENCY RELAYING - A method of transmitting data across an electronic data communication system comprising a plurality of terminals that can send and receive data in the form of electromagnetic waves to and from at least one of the terminals, which method comprises the steps of: (a) identifying at least one control terminal, at least one target terminal and at least two relaying terminals from the plurality of terminals; and (b) using the control terminal to instruct the at least two relaying terminals to receive and relay data intended for the at least one target terminal, so that the at least one target terminal can receive data directly from at least one terminal and from the at least two relaying terminals, thereby increasing capacity of the system. | 01-27-2011 |
| 20100297011 | ISOLATED PEPTIDES AND USES THEREOF - The present invention provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and/or said peptide-HLA complexes. Such compositions are useful in the treatment of Type 1 diabetes mellitus (T1DM). | 11-25-2010 |
| 20100291063 | PROTEASE INHIBITION - The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment. | 11-18-2010 |
| 20100273199 | Methods and Compositions - The invention relates to a method for aiding the diagnosis of a disorder in a subject, said method comprising; providing a sample from said subject wherein the sample comprises blood; assaying at least two characteristics of said sample, said characteristics selected from: the structural composition of a polypeptide comprised by said sample; a metabolite comprised by said sample; and a catalytic activity comprised by said sample, wherein each of said at least two characteristics is determined from a multiplexed analysis of the same sample. The invention also relates to certain compositions. | 10-28-2010 |
| 20100266493 | AGONIST ANTIBODIES AGAINST TSHR - The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides hybridomas for producing such antibodies. | 10-21-2010 |
| 20100247663 | MICROSPHERES - The invention relates to the production of microspheres having radial pores using thermally induced phase separation, especially microspheres for use in tissue engineering. | 09-30-2010 |
| 20100216664 | Method - The present invention relates, in one aspect, to a method for determining the severity of a disease attributed to at least one genetic mutation in one or more of the genes encoding haemoglobin polypeptide chains, comprising the steps of: (a) providing a sample from said subject; and (b) determining the presence of one or more diagnostic markers:
| 08-26-2010 |
| 20100216119 | Diagnostic Methods for HIV Infection - The invention relates to a method of aiding the diagnosis of a human immunodeficiency virus infection in a subject, said method comprising (i) providing a sample from the subject (ii) determining the level of ps20 in said sample (iii) comparing the level of ps20 of (ii) with the level of ps20 in an uninfected reference sample, wherein a higher level of ps20 in the sample from the subject compared to the uninfected reference sample indicates an increased likelihood of human immunodeficiency virus infection in said subject. The invention also relates to methods for assessing susceptibility of a subject to human immunodeficiency virus infection. Most suitably the ps20 level is determined via binding by an anti-ps20 antibody such as the 107 antibody. The invention also relates to kits for use in said methods. | 08-26-2010 |
| 20100159473 | Peptide Standards - The invention relates to methods for making a peptide standard for mass spectrometry said method comprising (a) identifying endopeptidase cleavage sites in a parent polypeptide sequence of interest; (b) selecting peptide sequences from said parent polypeptide which are defined by endopeptidase cleavage sites of step (a); (c) adding a C-terminal extension to each selected sequence; wherein if the endopeptidase cleavage site is C-terminal to its recognition sequence then the C-terminal extension comprises 1 to 6 amino acids, wherein if the endopeptidase cleavage site is N-terminal to its recognition sequence then the C-terminal extension comprises said recognition sequence, wherein if the endopeptidase cleavage site is within its recognition sequence then the C-terminal extension comprises the remainder of said recognition sequence C-terminal to the cleavage site; and (d) synthesising a peptide having the extended amino acid sequence of step (c). The invention also relates to peptide standards and methods of analysing samples. | 06-24-2010 |
| 20100047779 | BIOMARKERS - The present invention provides circulating biomarkers for conditions associated with metabolic syndrome, including diabetes mellitus, hypertension and congestive heart failure. The biomarkers include plasma DNA, neuron-specific enolase, 11β-hydroxysteroid dehydrogenase, rhodopsin, retinoschisin, RPE65 and cardiac troponin T. Methods and kits for detecting these biomarkers in the prediction, monitoring and diagnosing of disease are provided, particularly for determining mRNA levels thereof in a subject's blood. | 02-25-2010 |
| 20100029624 | Male Contraceptive - A compound having formula I. R | 02-04-2010 |
| 20090317831 | Sepsis Test - There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection. | 12-24-2009 |
| 20090317457 | ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN B-4 - The invention relates to a method of treating inflammatory conditions in a subject comprising administering to a subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also provides a method of promoting wound healing in a subject comprising administering to the subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to methods of treating the above mentioned conditions in a subject comprising administering to the subject a nucleic acid encoding a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also relates to pharmaceutical compositions comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant, or salt thereof, and a pharmaceutically acceptable carrier. | 12-24-2009 |
| 20090281026 | Use of BiP or a Variant, Homologue, Derivative or Fragment Thereof in the Manufacture of a Medicament for the Prevention or Treatment of Bone Loss or Bone Resorption - The present invention relates to the use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption. | 11-12-2009 |
| 20080317717 | ANTI-HEPATITIS B VIRUS RIBOZYMAL NUCLEIC ACID - This invention relates to ribozymes which cleave Hepatitis B Virus (HBV) at CUC sites. Suitable ribozymes may, for example, cleave at GGCUCUCUCGUCCC, CCUCAGCUCUGUAUCG or GAGGACUCUUGGA recognition sequences in HBV RNA. Ribozymal DNA, vector systems and pharmaceutical compositions are provided which may be useful, for example, in the treatment of HBV infection. | 12-25-2008 |
| 20080280345 | Screening Method - The present invention relates to a method for screening for variant peptides using mass spectrometry (MS). The present invention also relates to a system and a kit for performing the method. | 11-13-2008 |
